Trials / Available
AvailableNCT03576690
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Expanded Access Protocol for Emergency Use of REGN3470-3471-3479 for the Treatment of Ebola Virus Disease
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | REGN3470-3471-3479 |
Timeline
- First posted
- 2018-07-03
- Last updated
- 2025-11-24
Source: ClinicalTrials.gov record NCT03576690. Inclusion in this directory is not an endorsement.